[Funding alert] Sweden-based Sigrid Therapeutics Secures $4M in Funding

The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health.

Read also - Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)

SiPore21®, the company’s flagship product, is currently undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21® utilises a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.

Sana Alajmovic, Sigrid’s Co-Founder and CEO said, “This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective and safer solutions for obesity and diabetes management,”.

Mattias Ankarberg, Sigrid’s Chairman said, “Sigrid’s continued success is evident from the launch of one of the world’s largest ongoing prediabetes trials, SHINE, to SiPore21®’s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential,”.

Lars Molinder, financial adviser to Sigrid Therapeutics said, “We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions”.

About Sigrid Therapeutics

Sigrid Therapeutics is a Swedish impact unicorn dedicated to revolutionising obesity and diabetes management through its innovative SiPore® technology.

Read also - Amsterdam-based FIELDS Group Acquire IT-Infrastructure Service Provider TTNL

The company’s flagship product, SiPore21®, is currently in SHINE clinical trials, offering a natural, non-drug solution for prediabetes progression and weight control. With a focus on impactful innovation, Sigrid Therapeutics is committed to enhancing the well-being of individuals worldwide.